Entera Bio Reports Q2 2024 Financial Results, Provides Corporate Updates

JERUSALEM, Aug. 9, 2024 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”), a leader in the development of orally administered peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended June 30, 2024.

“We continue to deliver strong execution with key milestones achieved in Q2 2024 across each of our N-Tab oral peptide programs targeting patients with OBGYN/endocrinology, GI and metabolic diseases,” said Miranda Toledano, CEO of Entera. “Importantly, we are now just five months away from the FDA’s potential landmark decision on the ASBMR-FNIH SABER regulatory endpoint for osteoporosis drugs, which we view as an important catalyst for EB613. We are particularly eager to begin our pivotal study of EB613 in a much broader population where injectable anabolic drugs do not play a dominant role. Due to its potential dual mechanism of action, faster onset of action as an anabolic booster and oral minitablet delivery, we believe EB613 is uniquely positioned to support earlier osteoanabolic intervention in postmenopausal women at high risk of fracture,” she added.